for the lazy, busy or lukewarm: analyst datail

....."With a focus on stocks that are due to move through major inflection points in 2011 or companies that expect to
see strong operational growth. The investment mindset is to be on the lookout for stocks that will become the high achievers of 2011, in the way that Mesoblast and Acrux were in
2010......

Summary ? 'Bioshares' Top 10 Picks for 2011:

Company Code CMP Cap'n ($M) Investment Thesis

Alchemia ACL $0.73 $140 Fondparinux approval expected shortly

Bionomics BNO $0.34 $108 Drivers from interim data from multiple clinical trials

Biota Holdings BTA $1.28 $231 Potential early traction for Inavir in Japan

Clinuvel Pharmaceuticals CUV SP $2.14 MC $65M EU regualtory approval submission

Pharmaxis PXS SP $3.00 MC $678M European approval and launch of Bronchitol in Europe

Phylogica PYC SP $0.077 MC $22M Expects to sign three more library access deals in 2011

Sunshine Heart SHC SP $0.035 MC $35M Completion and positive results from feasability trial

Somnomed SOM SP $0.94 MC $38M Strong growth in unit sales to be maintained for FY2011

Starpharma Holdings SPL SP $0.84 MC $202M Platform technology base to continue to yield new partnerships,launch of condom microbicide product

Sirtex Medical SRX SP $6.12 MC $341M Shipping from Singapore facility to commence 2011 H1, return
to strong sales growth

I particularly like that PYC has the smallest market cap of all of these and has it's ongoing funding sorted out. The MD has made it clear that there are several mote deals in the bag, particularly with U.S. pharmaceutical corporations.

This is FYI and I hope some find it cheering or useful.

PatrickM